Wierzbicka-Tutka Iga, Sokołowski Grzegorz, Bałdys-Waligórska Agata, Adamek Dariusz, Radwańska Edyta, Gołkowski Filip
Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Cracow, Poland.
Department of Endocrinology, Jagiellonian University Medical College, Cracow, Poland.
Postepy Hig Med Dosw (Online). 2016 Nov 7;70(0):1117-1123. doi: 10.5604/17322693.1223796.
Prothymosin alpha (PTMA), a nuclear oncoprotein involved in cell cycle regulation, is used as a prognostic marker in many cancers. The histopathology of pituitary carcinomas and locally invasive adenomas is indistinguishable from that of benign tumors. A new marker is needed to differentiate these lesions. We evaluated PTMA in pituitary adenomas to determine its usefulness as a prognostic factor of tumor proliferation.
MATERIAL/METHODS: We conducted a retrospective analysis of a group of 27 patients, including 15 females (56%) and 12 males (44%) with a mean age of 58.6±12 years, who underwent pituitary tumor surgery between 2003 and 2012. The Ki-67 and PTMA-nuclear (PTMA-n) and PTMA-cytoplasmic (PTMA-c) indices were determined by immunohistochemical staining. We studied histopathological features, clinical symptoms, and magnetic resonance imaging or computed tomography performed before surgery and one year following surgery to evaluate tumor size and progression.
The expression of Ki-67 was revealed in 77.8% of adenomas, PTMA-n in 81.5% and PTMA-c in 92.6%. The mean value of the Ki-67 index was 1.8%, PTMA-n was 1.84%, and PTMA-c was 35.6%. There was a significant positive correlation between Ki-67 and PTMA-n (p=0.009). We did not find any correlation between Ki-67, PTMA-c, and tumor progression. PTMA-n was found to be correlated with tumor size (p=0.045) and was higher in the case of gonadotropinomas (p=0.026).
The positive nuclear expression of Ki-67 and PTMA was observed in the majority of pituitary adenomas. Neither the expression of Ki-67 nor that of PTMA-c was related to tumor recurrence or local invasion.
前胸腺素α（PTMA）是一种参与细胞周期调控的核癌蛋白，在许多癌症中用作预后标志物。垂体癌和局部侵袭性腺瘤的组织病理学与良性肿瘤难以区分。需要一种新的标志物来区分这些病变。我们评估了垂体腺瘤中的PTMA，以确定其作为肿瘤增殖预后因素的有用性。
材料/方法：我们对一组27例患者进行了回顾性分析，其中包括15名女性（56%）和12名男性（44%），平均年龄为58.6±12岁，他们在2003年至2012年期间接受了垂体肿瘤手术。通过免疫组织化学染色确定Ki-67以及PTMA核（PTMA-n）和PTMA胞质（PTMA-c）指数。我们研究了组织病理学特征、临床症状以及手术前和手术后一年进行的磁共振成像或计算机断层扫描，以评估肿瘤大小和进展情况。
77.8%的腺瘤中检测到Ki-67表达，81.5%检测到PTMA-n表达，92.6%检测到PTMA-c表达。Ki-67指数的平均值为1.8%，PTMA-n为1.84%，PTMA-c为35.6%。Ki-67与PTMA-n之间存在显著正相关（p = 0.009）。我们未发现Ki-67、PTMA-c与肿瘤进展之间存在任何相关性。发现PTMA-n与肿瘤大小相关（p = 0.045），在促性腺激素瘤中更高（p = 0.026）。
大多数垂体腺瘤中观察到Ki-67和PTMA的阳性核表达。Ki-67和PTMA-c的表达均与肿瘤复发或局部侵袭无关。
